Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization Peter A. Soden, MD, Sara L. Zettervall, MD, MPH, Klaas H.J. Ultee, BSc, Bruce E. Landon, MD, MBA, A. James O'Malley, PhD, Philip P. Goodney, MD, MS, Randall R. DeMartino, MD, MS, Shipra Arya, MD, Marc L. Schermerhorn, MD Journal of Vascular Surgery Volume 64, Issue 6, Pages 1633-1644.e1 (December 2016) DOI: 10.1016/j.jvs.2016.05.098 Copyright © 2016 Society for Vascular Surgery Terms and Conditions
Fig Cumulative adjusted survival for patients with critical limb ischemia (CLI) undergoing (A) bypass and (B) endovascular intervention. ASA, Aspirin; CI, confidence interval; DAPT, dual antiplatelet therapy; HR, hazard ratio. Journal of Vascular Surgery 2016 64, 1633-1644.e1DOI: (10.1016/j.jvs.2016.05.098) Copyright © 2016 Society for Vascular Surgery Terms and Conditions
Supplementary Fig (online only) Cumulative adjusted survival for patients undergoing (A) bypass and (B) endovascular intervention. ASA, Aspirin; CI, confidence interval; DAPT, dual antiplatelet therapy; HR, hazard ratio. Journal of Vascular Surgery 2016 64, 1633-1644.e1DOI: (10.1016/j.jvs.2016.05.098) Copyright © 2016 Society for Vascular Surgery Terms and Conditions